MarketCap
Facebook
X
Telegram
Insulet Corporation Financial Ratios 2025-2008 | PODD
Brief overview of Insulet Corporation's market valuation
The review covers five available annual periods spanning 2021 to 2025.
The valuation comparison uses P/E 73.41x (median 73.41x), EV/EBITDA 33.85x (median 52.94x), P/S 6.7x (median 9.51x). Multiples are on average 32.3% below their own medians. Shares look cheaper than their recent historical valuation.
The 1/P/E calculation produces a 1.4% earnings yield. It does not capture future growth or capital structure.
Returns on assets and capital are represented by ROE 16.3%, ROA 7.7%, ROCE 31.3%. Returns on capital and assets point to efficient economics and a strong internal source of growth.
Price, earnings and growth produce a PEG of 1.29x, a neutral level if forecasts are realistic.
The cash conversion cycle shortened from 233.2 days to 187.2 days, or 45.9 days. Working capital returns faster.
Valuation takeaway
Insulet Corporation's high-quality returns come with historically restrained multiples. Price appears more cautious than current business efficiency.
Annual Financial Ratios Insulet Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
73.4 | 47.1 | 62.8 | 3096.4 | 999.4 | 2543.5 | 1013.6 | 482.7 | -165.6 | -82.3 | -25.6 | -31.7 | -52.1 | -21.5 | -16.0 | -9.4 | - | - |
P/S |
6.7 | 9.5 | 7.6 | 10.9 | 15.3 | 19.1 | 15.9 | 8.5 | 9.6 | 6.5 | 5.8 | 5.7 | 9.5 | 5.3 | 6.0 | - | - | - |
EPS |
3.5 | 6.0 | 3.0 | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | -0.5 | -0.5 | -1.3 | -0.9 | -0.8 | -1.1 | -1.0 | -1.5 | -2.4 | - |
EV (Enterprise Value) |
19.1 B | 20.6 B | 14.1 B | 15.3 B | 17.5 B | 17.7 B | 12.6 B | 5.38 B | 4.82 B | 2.63 B | 2 B | 1.7 B | 2.36 B | 1.21 B | 957 M | 550 M | -128 M | -56.7 M |
EBITDA per Share |
8.02 | 5.56 | 4.2 | 1.45 | 2.71 | 1.65 | 1.29 | 0.73 | 0.11 | 0.0547 | -0.791 | -0.00133 | -0.321 | -0.52 | -0.727 | -0.85 | - | - |
EV/EBITDA |
33.9 | 52.9 | 48.2 | 152.1 | 95.3 | 166.2 | 161.8 | 116.2 | 738.3 | 821.7 | -43.0 | -22334.1 | -133.1 | -47.2 | -27.3 | -16.4 | 2.4 | - |
PEG |
1.29 | 0.88 | 1.01 | 22.57 | 5.99 | 19.19 | 0.08 | 0.04 | -0.01 | -1.36 | 0.66 | 2.63 | -2.25 | -1.87 | -0.77 | - | - | - |
P/B |
12.0 | 16.3 | 17.7 | 29.9 | 30.2 | 28.7 | 154.9 | 22.5 | 28.0 | 37.6 | 55.3 | 19.5 | 18.8 | 25.2 | 12.8 | 8.7 | - | - |
P/CF |
31.9 | 45.8 | 88.9 | 119.7 | -246.5 | 205.9 | 119.5 | 133.1 | 107.5 | -382.9 | -81.4 | -637.1 | -591.7 | -27.8 | -25.0 | -16.1 | - | - |
ROE % |
16.31 | 34.52 | 28.16 | 0.97 | 3.02 | 1.13 | 15.28 | 4.67 | -16.91 | -45.73 | -215.91 | -61.43 | -36.10 | -117.41 | -80.07 | -92.34 | -116.85 | - |
ROA % |
7.75 | 13.55 | 7.97 | 0.20 | 0.82 | 0.36 | 1.01 | 1.07 | -3.28 | -6.32 | -26.72 | -17.04 | -15.62 | -26.19 | -27.28 | -39.15 | - | - |
ROCE % |
31.27 | 25.50 | 30.04 | 7.89 | 22.65 | 3.09 | 5.08 | 3.37 | -1.01 | -2.67 | -28.94 | -4.77 | -11.86 | -24.02 | -23.39 | -58.33 | -95.88 | - |
Current Ratio |
1.9 | 1.6 | 1.4 | 1.3 | 1.4 | 1.5 | 1.1 | 1.3 | 1.2 | 6.6 | 2.9 | 4.7 | 4.7 | 2.3 | 4.7 | 1.7 | - | - |
DSO |
- | - | 15.2 | 42.2 | 40.7 | 30.9 | 32.8 | 37.8 | 32.3 | 28.6 | 54.5 | 50.4 | 48.8 | 57.5 | 55.6 | - | - | - |
DIO |
209.8 | 242.9 | 254.6 | 237.4 | 240.8 | 144.7 | 122.0 | 99.2 | 67.8 | 83.1 | 29.1 | 32.9 | 25.6 | 45.6 | 50.5 | 39.2 | - | - |
DPO |
22.5 | 11.4 | 17.0 | 25.0 | 48.3 | 61.5 | 56.6 | 47.1 | 36.7 | 30.8 | 38.7 | 36.8 | 52.5 | 28.7 | 48.7 | 16.8 | - | - |
Operating Cycle |
209.8 | 242.9 | 269.7 | 279.6 | 281.5 | 175.6 | 154.8 | 136.9 | 100.1 | 111.8 | 83.6 | 83.3 | 74.5 | 103.1 | 106.1 | 39.2 | - | - |
Cash Conversion Cycle |
187.2 | 231.5 | 252.8 | 254.6 | 233.2 | 114.0 | 98.2 | 89.9 | 63.4 | 81.0 | 44.9 | 46.5 | 22.0 | 74.4 | 57.4 | 22.4 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Insulet Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.3 | 1.24 | 0.32 | 0.5 | - | 1.11 | 2.69 | 0.74 | - | 0.74 | 0.39 | 0.34 | - | -0.08 | -0.5 | 0.4 | - | 0.18 | -0.37 | - | - | 0.18 | 0.22 | -0.03 | 0.08 | 0.01 | 0.02 | 0.07 | 0.17 | 0.03 | -0.03 | -0.11 | -0.12 | -0.04 | -0.13 | -0.17 | -0.16 | -0.05 | -0.08 | -0.19 | -0.28 | -0.31 | -0.3 | -0.18 | -0.1 | -0.19 | -0.53 | -0.11 | -0.04 | -0.39 | -0.2 | -0.2 | -0.21 | -0.26 | -0.3 | -0.31 | -0.3 | -0.29 | -0.42 | -0.22 |
EBITDA per Share |
2.12 | 1.71 | 1.76 | 1.57 | - | 1.29 | 0.81 | 1.08 | - | - | - | 0.65 | - | 0.04 | -0.38 | 0.77 | - | 0.51 | 0.42 | 0.44 | 0.22 | 0.81 | 0.71 | 0.26 | - | 0.59 | 0.31 | 0.21 | 0.27 | 0.31 | 0.19 | 0.06 | -0.01 | 0.22 | 0.06 | -0.03 | -0.07 | 0.22 | 0.1 | -0.07 | -0.22 | -0.06 | -0.12 | -0.07 | - | 0.11 | 0.01 | 0.02 | - | -0.16 | - | -0.06 | - | -0.01 | -0.1 | -0.17 | - | -0.09 | -0.26 | -0.13 |
ROE % |
17.52 | 17.46 | 30.02 | 35.00 | 32.34 | 40.88 | 38.88 | 24.72 | 18.21 | 16.99 | 0.16 | 1.46 | -3.28 | -0.75 | -4.98 | 5.26 | -0.97 | 1.59 | -4.50 | 0.95 | 0.95 | 7.53 | 6.12 | 4.12 | 9.65 | 7.73 | 8.00 | 6.64 | 1.56 | -7.44 | -9.65 | -13.74 | -16.93 | -27.05 | -30.52 | -32.27 | -45.74 | -111.54 | -162.25 | -200.92 | -215.91 | -142.10 | -99.45 | -88.86 | -61.43 | -57.00 | -61.15 | -34.87 | -36.10 | -57.16 | -68.19 | -92.51 | -117.41 | -111.66 | -99.95 | -76.95 | -55.39 | -16.39 | -9.77 | -11.90 |
ROA % |
7.60 | 7.11 | 10.76 | 12.08 | 11.07 | 13.17 | 11.76 | 6.25 | 4.29 | 4.05 | 0.29 | 0.49 | -0.55 | 0.08 | -0.98 | 1.35 | 0.01 | 0.89 | 0.07 | 1.37 | 1.37 | 1.81 | 1.20 | 0.44 | 1.01 | 1.64 | 1.76 | 1.45 | 0.36 | -1.55 | -2.01 | -2.77 | -3.29 | -4.44 | -4.84 | -4.81 | -6.32 | -14.26 | -20.46 | -25.15 | -26.72 | -18.61 | -15.32 | -19.34 | -17.07 | -16.13 | -19.93 | -13.95 | -15.62 | -19.90 | -18.77 | -22.43 | -26.19 | -27.52 | -27.38 | -23.72 | -20.71 | -6.13 | -3.65 | -4.45 |
ROCE % |
32.83 | 31.34 | 28.29 | 27.21 | 20.54 | 29.56 | 27.29 | 27.34 | 20.14 | 20.82 | 5.48 | 8.35 | 2.84 | 9.61 | 14.66 | 23.77 | 15.28 | 19.28 | 17.40 | 24.38 | 21.59 | 32.88 | 31.92 | 30.31 | 17.60 | 25.25 | 17.20 | 16.19 | 12.44 | 6.08 | 0.73 | -1.31 | -4.66 | -10.73 | -8.19 | -8.11 | -16.96 | -47.46 | -94.73 | -133.98 | -143.13 | -109.50 | -72.36 | -33.32 | -11.98 | -25.87 | -27.12 | -25.80 | -23.55 | -42.72 | -52.64 | -72.63 | -67.65 | -79.46 | -78.31 | -63.29 | -38.62 | -11.81 | -18.03 | -8.79 |
Current Ratio |
1.8 | 1.8 | 1.7 | 1.6 | 1.6 | 1.6 | 1.5 | 1.4 | 1.4 | 1.3 | 1.3 | 1.3 | 1.3 | 1.2 | 1.2 | 1.3 | 1.4 | 1.3 | 1.3 | 1.5 | 1.5 | 1.5 | 1.5 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.3 | 1.3 | 1.3 | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.1 | 1.1 | 1.1 | 1.4 | 1.4 | 1.4 | 1.4 | 1.8 | 1.8 | 1.8 | 1.8 | 1.3 | 1.3 | 1.3 | 1.3 | 1.6 | 1.6 | 1.6 | 1.6 |
DSO |
32.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.6 | - | 35.5 | 34.4 | 34.9 | - | 32.7 | 33.8 | 35.3 | 30.2 | 32.9 | 35.7 | 37.9 | 35.0 | 38.2 | 46.5 | 43.1 | 37.3 | 40.0 | 44.4 | 36.9 | 25.4 | 27.7 | 30.1 | 40.1 | 46.3 | 54.4 | 64.1 | 73.7 | 58.7 | 48.5 | 50.5 | 48.1 | 44.0 | 49.4 | 50.2 | 52.8 | 52.5 | 55.5 | 59.5 | 54.0 | 44.8 | 47.5 | 65.7 | - |
DIO |
178.2 | 207.7 | 205.7 | - | - | 239.6 | 249.4 | - | - | - | - | - | - | - | - | 329.0 | - | 239.8 | 208.5 | 174.5 | - | 126.9 | 108.6 | 126.2 | - | 133.6 | 151.8 | 148.7 | - | 132.7 | 154.5 | 100.5 | - | 64.0 | 68.3 | 74.7 | - | 82.6 | 87.9 | 58.4 | - | 27.6 | 36.5 | 56.5 | - | 32.4 | 33.0 | 28.3 | - | 25.6 | 26.0 | 34.5 | - | 44.7 | 47.3 | 44.4 | - | 41.5 | 61.1 | - |
DPO |
38.8 | 33.6 | 35.6 | - | - | 32.0 | 44.2 | - | - | - | - | - | - | - | - | 47.9 | - | 56.3 | 61.4 | 60.9 | - | 51.4 | 39.2 | 58.3 | - | 72.1 | 81.9 | 69.0 | - | 47.4 | 55.1 | 47.7 | - | 46.3 | 49.4 | 40.5 | - | 30.6 | 32.6 | 34.8 | - | 34.9 | 46.2 | 66.9 | - | 36.2 | 36.9 | 42.7 | - | 52.4 | 53.1 | 40.7 | - | 28.1 | 29.8 | 34.5 | - | 40.0 | 59.0 | - |
Operating Cycle |
- | 207.7 | 205.7 | - | - | 239.6 | 249.4 | - | - | - | - | - | - | - | - | 373.6 | - | 275.4 | 242.9 | 209.5 | - | 159.6 | 142.3 | 161.5 | 30.2 | 166.5 | 187.5 | 186.6 | 35.0 | 170.9 | 201.0 | 143.6 | 37.3 | 104.0 | 112.7 | 111.6 | 25.4 | 110.3 | 118.0 | 98.4 | 46.3 | 81.9 | 100.6 | 130.2 | 58.7 | 80.9 | 83.5 | 76.4 | 44.0 | 75.0 | 76.2 | 87.3 | 52.5 | 100.2 | 106.8 | 98.3 | 44.8 | 88.9 | 126.8 | - |
Cash Conversion Cycle |
- | 174.2 | 170.1 | - | - | 207.5 | 205.2 | - | - | - | - | - | - | - | - | 325.7 | - | 219.0 | 181.4 | 148.6 | - | 108.2 | 103.2 | 103.2 | 30.2 | 94.4 | 105.6 | 117.6 | 35.0 | 123.5 | 145.8 | 95.9 | 37.3 | 57.8 | 63.3 | 71.1 | 25.4 | 79.7 | 85.4 | 63.6 | 46.3 | 47.0 | 54.4 | 63.3 | 58.7 | 44.7 | 46.6 | 33.8 | 44.0 | 22.6 | 23.1 | 46.6 | 52.5 | 72.0 | 77.0 | 63.8 | 44.8 | 48.9 | 67.9 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Insulet Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
France
China
Israel
Canada
